July 25, 2019
Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out?
In the biological sciences, that can be a very tricky question, as six-year-old startup Recursion Pharmaceuticals has learned from experience. The amount of data expands rapidly and knowing how to frame an objective that yields insights from the data is something of an art.
“It’s still a big data problem,” says Mason Victors, chief technologist of Recursion, which is based in Salt Lake City, Utah. “We have chosen a very large swath of biology on which to develop our platform over many years,” he said in an interview with ZDNet. And that brings challenges.
The company gathers 65 terabytes of data per week, which it stores in Google’s cloud computing facility. Recursion has amassed roughly 2.5 petabytes of information in a little over four years.
Recursion is trying to do two things that are complementary but also hugely ambitious. Nominally, Recursion’s mission is to find cures for diseases, in a way that cuts down on the costly pipeline of development.
To continue reading, click here: https://www.zdnet.com/article/the-subtle-art-of-really-big-data-recursion-maps-the-body/